Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. - Wikidata - awgldk - TriplyDB

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

http://www.wikidata.org/entity/Q34729698

about

New perspectives on targeted therapy in ovarian cancer Type-specific cell line models for type-specific ovarian cancer research Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems The transcriptomic profile of ovarian cancer grading Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.Recent progress in the diagnosis and treatment of ovarian cancer The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors.Prediction of anti-angiogenesis escape.The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.Genetic and molecular changes in ovarian cancer.Diagnostic potential of tumor DNA from ovarian cyst fluid.Ovarian cancer: genomic analysis.Clinical implications of using molecular diagnostics for ovarian cancers.Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.Cyberknife radiotherapy and anastrozole for the treatment of advanced progressive low-grade papillary serous ovarian carcinoma: A case report.Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary.Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.Low-grade serous carcinoma: molecular features and contemporary treatment strategies.Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.

P2860

Q28082524-682A13FF-F755-4AA2-AA79-ACDED178F7F2 Q28536689-65BE9EDE-5996-4066-A0B3-13565F66807A Q33735170-AE345428-77C4-48A6-842C-6501E0BE96F9 Q34097804-97307599-2E89-417C-9D6C-1FF269F8DD4D Q34162272-CAB77A87-8944-4696-9917-10F74ECD3E26 Q34387999-9CAD922C-F893-42C2-9EDC-D58F9191B0A1 Q34579904-37C536F5-AD56-458D-AF29-967EF1954341 Q34626854-79A39C3D-11CA-4716-AF7C-6600F05CCCEA Q34998994-B38E62EF-9224-4062-B576-438DA748CEA2 Q35032309-9D2F1E52-7EEB-48C5-891D-ECDBFBC143BA Q35060446-2B341FBC-478C-4CF3-9961-ED8EFEF8DB43 Q35209365-0CAA7162-4DA7-49C0-835B-B1E848BFD750 Q35461505-F536A8EE-599B-4093-93A7-28A020FD5769 Q35510378-B36B2F04-289A-40CE-B1C9-3533285589F2 Q35872796-05E70676-F8A3-436C-B35F-A0FE60BEE7FF Q35947034-A1D1AB51-E836-4B2F-A4D4-59FC5B9F140C Q35983825-C2D63385-93ED-4CB0-8634-6FDE6844BA84 Q36346403-24E8541C-E813-45A6-BABC-236DB9C50081 Q36346641-D7F836AC-B552-4302-AC38-F0143896C422 Q36604195-A7751BD4-B36C-4113-908D-25947A7485A5 Q36622857-972B22AA-0377-4A01-9A26-0972463EA02A Q36651350-E1D8CB90-0478-48FF-B9A1-11FBA33BEA1C Q36730777-C3FEB9F9-DF4C-45D0-95FD-DF9CDA1B6DB6 Q36751103-6666A042-B9C4-4528-ACD3-83DDB40F4370 Q36768921-0E857C89-8625-4B29-8810-5D4B7E423EB9 Q36855239-893D5661-CA43-4124-B68D-497CCDC1E136 Q36937081-25CCFBC7-CEE4-41FA-9E9C-4DA3BA91F9BE Q37094076-049B8CFA-7ACD-4612-BD9E-27BC6B49574C Q37098838-3859D027-F2AD-4BE6-B576-1EC44531F777 Q37332480-5952B22B-DA0D-4C44-9EBC-00507E3165E5 Q37332490-A8495E68-ED6A-4855-8DFF-09459B73C2EF Q37382527-663BEB48-0F84-48D4-A3C1-5B02A4FBB519 Q37390070-3AF30972-4D8B-4289-B0C3-7BD99E9D3251 Q37604669-82B23D23-B91D-4AC7-8710-35C4F845E603 Q37652173-D0E3B1C4-346C-4AC4-9B70-662DFD846C6D Q37724181-CF4DAE76-4EC0-407A-8C6D-7CF562B275F6 Q37988903-156C64B1-B4CA-4E68-8C4A-9ACF3B5F26C6 Q38096241-890DF968-360B-4838-8687-98D277075754 Q38514737-E7555878-9909-465B-ABDD-EA3E5F5D0D04 Q38856683-A63A76AB-59D6-4BA6-943F-3C6F6E21CD5F

P2860

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

http://www.wikidata.org/entity/Q34729698

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@ast

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@en

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@nl

type

label

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@ast

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@en

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@nl

prefLabel

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@ast

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@en

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@nl

P1433

Q34729698-3AA103FB-A0BD-43D6-85C8-8F86B840DD41

P1476

Q34729698-36D255F1-5634-441E-A21C-BC53F744861E

P2093

Q34729698-03B937C3-D129-430B-9B82-605B8929841C

Q34729698-19DEFD4C-4C3D-4898-9824-93ED79D8493A

Q34729698-3E11FE6C-6E05-408D-8B49-6322E4F72C27

Q34729698-5E4D1CFE-FCDA-4F30-AB26-F877741070DA

Q34729698-642FD874-D723-4B69-BBFB-BF8E5BD6A406

Q34729698-888AD899-D94C-4A81-B7BB-C54425077BF7

Q34729698-91B66AC1-22BD-4B0C-BC68-814EA6D0568F

P304

Q34729698-7F8EDC0B-C491-4A3E-B112-9AC4BC76FBF9

P31

Q34729698-7365ADB4-6DF1-4270-BB9D-E05E6042AFB3

P356

Q34729698-FF693AF2-C284-44A0-915D-C4EF14671310

P407

Q34729698-30F3D455-A9BB-47F7-954E-245C0A81CCA6

P433

Q34729698-919DE8BE-696E-494A-95B9-FEC5E6B1670A

P478

Q34729698-52BC0D5B-C780-4D64-A77B-B9900853B89E

P50

Q34729698-288269D7-C903-48FA-8C42-845C7B9A0C45

P577

Q34729698-6FA53E08-603C-48C3-835F-8EEF616F9947

P698

Q34729698-50CD538A-2D02-485E-9838-67210BF89C13

P921

Q34729698-CC225270-9D03-4128-B3E3-5C47A925FA58

P356

J.YGYNO.2007.11.013

P1433

Gynecologic Oncology

P1476

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

@en

P2093

Charlotte C Sun

http://www.w3.org/2001/XMLSchema#string

David M Gershenson

http://www.w3.org/2001/XMLSchema#string

Diane C Bodurka

http://www.w3.org/2001/XMLSchema#string

Kathleen M Schmeler

http://www.w3.org/2001/XMLSchema#string

Michael T Deavers

http://www.w3.org/2001/XMLSchema#string

Pedro T Ramirez

http://www.w3.org/2001/XMLSchema#string

Robert L Coleman

http://www.w3.org/2001/XMLSchema#string

P304

510-514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2007.11.013

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-12-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18155273

http://www.w3.org/2001/XMLSchema#string

P921